RESEARCH TRIANGLE PARK – A host of companies across North Carolina are reporting earnings this week, including CommScope, Biocryst, BDSI and more. Here’s a look:

  • COMMSCOPE

HICKORY – CommScope Holding Co. (COMM) on Thursday reported a loss of $97.6 million in its first quarter.

On a per-share basis, the Hickory, North Carolina-based company said it had a loss of 55 cents. Earnings, adjusted for one-time gains and costs, were 36 cents per share.

The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 31 cents per share.

The wireless and broadband network technology company posted revenue of $2.07 billion in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $2.01 billion.

CommScope shares have risen 24% since the beginning of the year. The stock has increased 64% in the last 12 months.

  • BIOCRYST

DURHAM – BioCryst Pharmaceuticals Inc. (BCRX) on Thursday reported a loss of $64.3 million in its first quarter.

On a per-share basis, the Durham, North Carolina-based company said it had a loss of 36 cents.

The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 26 cents per share.

The drugmaker posted revenue of $19.1 million in the period, beating Street forecasts. Three analysts surveyed by Zacks expected $12.8 million.

BioCryst shares have climbed 43% since the beginning of the year. The stock has more than doubled in the last 12 months.

  • BDSI

RALEIGH – BioDelivery Sciences International Inc. (BDSI) on Thursday reported first-quarter net income of $5.2 million.

The Raleigh, North Carolina-based company said it had net income of 5 cents per share.

The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 7 cents per share.

The specialty pharmaceutical company posted revenue of $41 million in the period, matching Street forecasts.

BioDelivery expects full-year revenue in the range of $170 million to $180 million.

The company’s shares closed at $3.41. A year ago, they were trading at $4.42.

  • CHIMERIX

DURHAM – Chimerix Inc. (CMRX) on Thursday reported a loss of $97.4 million in its first quarter.

The Durham, North Carolina-based company said it had a loss of $1.21 per share. Losses, adjusted for research and development costs, were 18 cents per share.

The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 48 cents per share.

The biopharmaceutical company posted revenue of $1.4 million in the period.

Chimerix shares have climbed 81% since the beginning of the year. The stock has more than tripled in the last 12 months.

  • VTV THERAPEUTICS

HIGH POINT – VTv Therapeutics Inc. (VTVT) on Wednesday reported a loss of $4.2 million in its first quarter.

The High Point, North Carolina-based company said it had a loss of 8 cents per share. Losses, adjusted for non-recurring gains, were 9 cents per share.

The biopharmaceutical company posted revenue of $987,000 in the period.

In the final minutes of trading on Wednesday, the company’s shares hit $2.43. A year ago, they were trading at $2.09.

  • AERIE PHARMACEUTICALS

DURHAM – Aerie Pharmaceuticals Inc. (AERI) on Wednesday reported a loss of $42 million in its first quarter.

On a per-share basis, the North Carolina, North Carolina-based company said it had a loss of 91 cents. Losses, adjusted for non-recurring costs, were 72 cents per share.

The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 69 cents per share.

The drugmaker posted revenue of $23 million in the period, also missing Street forecasts. Five analysts surveyed by Zacks expected $23.4 million.

Aerie shares have increased 25% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $16.84, a rise of slightly more than 5% in the last 12 months.